Please login to the form below

Not currently logged in
Email:
Password:

Further EU approval for Novartis' Afinitor

Novartis' cancer therapy Afinotor has been granted an additional EU approval for use in the treatment of patients with an advanced form of pancreatic cancer

Novartis' cancer therapy Afinotor (everolimus) has been granted new European Union (EU) approval for use as a treatment for patients with an advanced form of pancreatic cancer.

The drug, which is also approved for patients with advanced renal cell carcinoma, can now be used as for the treatment of neuroendocrine tumours (NET) of pancreatic origin that have either spread to other parts of the body or cannot be removed by surgery. About 60 per cent of patients diagnosed with pancreatic NET have an advanced form of the disease.

The approval follows a phase III trial that showed Afinitor more than doubled the length of time patients went without tumour growth when compared with placebo.

The decision applies in all 27 EU member states, as well as Iceland and Norway.

Hervé Hoppenot, president of Novartis Oncology, said the decision would benefit thousands of patients across Europe who have limited therapy options.

Novartis is continuing to develop the drug for other forms of cancer.

5th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics